Evidence map›Paper›PMID 23677863›Full record

ArticleThe Journal of nutrition2013

Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.

Hema L Ramkumar, Jingsheng Tuo, De F Shen, Jun Zhang, Xiaoguang Cao, Emily Y Chew, Chi-Chao Chan

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of nutrition, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Novel Therapeutic Effects ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  6. Observational
  7. Review
  8. Protective Effects ofAntioxidants (Basel, Switzerland) · 2023
    Article
  9. Protective Effect ofAntioxidants (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Nutrients · 2021
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Hema L RamkumarLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Jingsheng Tuo
De F Shen
Jun Zhang
Xiaoguang Cao
Emily Y Chew
Chi-Chao Chan
National Institutes of Health · US

Funding

Histopathology CoreZICEY000461 · NEI · NATIONAL EYE INSTITUTE · PI SCHNEEWEIS, DAVID · 2009 to 2022
$7.7M
Molecular And Immunopathology Of Experimental And Clinical Ocular DiseasesZIAEY000222 · NEI · NATIONAL EYE INSTITUTE · PI CHAN, CHI-CHAO · 2009 to 2015
$7.2M
Age-Related Macular Degeneration: Genetic Variations and Animal ModelZIAEY000418 · NEI · NATIONAL EYE INSTITUTE · PI CHAN, CHI-CHAO · 2009 to 2015
$6.0M
Howard Hughes Medical InstituteIntramural NIH HHS
6 · The paper itself

Abstract

The Age-Related Eye Diseases Study 2 (AREDS2) clinical trial is assessing the effects of higher dietary xanthophyll (lutein and zeaxanthin) and long-chain n3 polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) intake on progression to advanced age-related macular degeneration (AMD). This study's purpose was to examine the retinal effects of the AREDS2 formulation on Chemokine (C-C motif) ligand 2 (Ccl2(-/-))/CX3C chemokine receptor 1 (Cx3cr1(-/-)) mice on Crumbs homolog 1 retinal degeneration phenotype 8 (Crb1(rd8)) background (DKO), which develop focal retinal lesions with certain features similar to AMD. DKO and C57BL/6N rd8 background mice (WT) were bred and randomized into 4 groups. Two groups, WT mice on AREDS2 diet (A-WT) and DKO mice on AREDS2 diet (A-DKO), were supplemented daily with 1.76 μmol of lutein, 35.1 μmol of zeaxanthin, 215 μmol EPA, and 107 μmol of DHA, and 2 control groups, WT mice on control diet (C-WT) and DKO mice on control diet (C-DKO), were fed an isocaloric diet. All mice had monthly fundus photos and were killed after 3 mo for biochemical and histologic analyses. After 3 mo, 81% of A-DKO mice had lesion regression compared with 25% of C-DKO mice (P < 0.05). Toxic retinal 2-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetra-enyl]-1-(2-hydroxyethyl)-4-[4-methyl-6(2,6,6-trimethyl-1-cyclohexen-1-yl) 1E,3E,5E,7E-hexatrienyl]-pyridinium (A2E) concentrations were significantly lower in A-DKO compared with C-DKO mice. The outer nuclear layer thickness in A-DKO mice was significantly greater than that in C-DKO mice. Retinal expression of inducible nitric oxide synthase (iNos) tumor necrosis factor-α (Tnf-α), Cyclooxygenase-2 (Cox-2), interleukin1beta (IL-1β), and vascular endothelial growth factor (Vegf) was significantly lower in A-DKO compared with C-DKO mice. Xanthophylls and LCPUFAs have antiinflammatory, neuroprotective, and antiangiogenic properties. Our data provide potential mechanisms by which the AREDS2 formula has a protective effect on retinal lesions in DKO mice.

Indexed as

Dietary SupplementsAngiogenesis InhibitorsAnimalsAnti-Inflammatory AgentsChemokine CCL2CX3C Chemokine Receptor 1Cyclooxygenase 2Docosahexaenoic AcidsEicosapentaenoic AcidGene Expression ProfilingInterleukin-1betaLuteinMacular DegenerationMiceMice, Inbred C57BLMice, KnockoutA2-E (N-retinylidene-N-retinylethanolamine)Angiogenesis InhibitorsAnti-Inflammatory AgentsCcl2 protein, mouseChemokine CCL2CX3C Chemokine Receptor 1Cx3cr1 protein, mouseCyclooxygenase 2Docosahexaenoic AcidsEicosapentaenoic AcidInterleukin-1betaLuteinNitric Oxide Synthase Type IINos2 protein, mousePtgs2 protein, mousePyridinium CompoundsReceptors, ChemokineRetinoidsTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseXanthophyllsZeaxanthins

Identifiers

PMID23677863
PMCPMC3681547
OpenAlexW2159535906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.